An Exploratory, Open-label, Multicenter Phase Ib Trial to Evaluate Safety and Efficacy of Sym021 Anti-PD-1 in Combination with Either Sym022 Anti-LAG-3 or Sym023 Anti-TIM-3 or Sym023 and Irinotecan in Patients with Selected Solid Tumor Malignancies

Brief Summary

Type:
Other

Study Type:
Treatment

Phase:
I

ClinicalTrials.gov Identifier:
NCT04641871

Study #:
STUDY00146742

Start Date:
May 02, 2022

Full Details and Eligibility at clinicaltrials.gov

By taking part in a clinical trial, you have access to potentially effective treatments not available elsewhere. Additionally, you will contribute to cancer research, which can help other cancer patients in the future. Read the full details of this specific clinical trial by clicking on the link below.

ClinicalTrials.gov ID: NCT04641871

View Complete Trial Details & Eligibility at ClinicalTrials.gov